Literature DB >> 20180278

Strategies toward CNS-regeneration using induced pluripotent stem cells.

Hideyuki Okano1.   

Abstract

Induced pluripotent stem (iPS) cells are pluripotent stem cells directly reprogrammed from cultured mouse fibroblast by introducing Oct3/4, Sox2, c-Myc, and Klf4. Cells obtained using this technology, which allows the ethical issues and immunological rejection associated with embryonic stem (ES) cells to be avoided, might be a clinically useful source for cell replacement therapics. Here we demonstrate that murine iPS cells formed neurospheres that produced electrophysiologically functional neurons, astrocytes, and oligodendrocytes. Secondary neurospheres (SNSs) generated from various mouse iPS cell showed their neural differentiation capacity and teratoma formation after transplantation into the brain of immunodeficient NOD/SCID mice. We found that origin (source of somatic cells) of the iPS cells are the crucial determinant for the potential tumorigenicity of iPS-derived neural stem/progenitor cclls and that their tumorigenicity results from the persistent presence of undifferentiated cells within the SNSs. Furthermore, transplantation of non-tumorigenic Nanog-iPS-derived SNSs into mouse spinal cord injury (SCI) model promoted locomotor function recovery. Surprisingly, SNSs derived from c-Myc minus iPS cells generated without drug selection showed robust tumorigenesis, in spite of their potential to contribute adult chimeric mice without tumor formation.

Entities:  

Mesh:

Year:  2009        PMID: 20180278

Source DB:  PubMed          Journal:  Genome Inform        ISSN: 0919-9454


  5 in total

Review 1.  Biomarkers in Spinal Cord Injury: from Prognosis to Treatment.

Authors:  Leonardo Fonseca Rodrigues; Vivaldo Moura-Neto; Tania Cristina Leite de Sampaio E Spohr
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

2.  HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development.

Authors:  Kiyoshi Kikuchi; Hisaaki Uchikado; Naoki Miura; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Kei Miyata; Rokudai Sakamoto; Chiemi Kikuchi; Narumi Iida; Naoto Shiomi; Terukazu Kuramoto; Naohisa Miyagi; Ko-Ichi Kawahara
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

3.  Ethical implications in the use of embryonic and adult neural stem cells.

Authors:  Rodrigo Ramos-Zúñiga; Oscar González-Pérez; Ana Macías-Ornelas; Vivian Capilla-González; Alfredo Quiñones-Hinojosa
Journal:  Stem Cells Int       Date:  2012-09-10       Impact factor: 5.443

4.  Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration.

Authors:  Hoshimi Kanemura; Masahiro J Go; Masayuki Shikamura; Naoki Nishishita; Noriko Sakai; Hiroyuki Kamao; Michiko Mandai; Chikako Morinaga; Masayo Takahashi; Shin Kawamata
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240

Review 5.  Stem cell therapy for central nerve system injuries: glial cells hold the key.

Authors:  Li Xiao; Chikako Saiki; Ryoji Ide
Journal:  Neural Regen Res       Date:  2014-07-01       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.